Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasms 9Sarcoma 5Recurrence 5Neoplasm Metastasis 5Lymphoma 5Breast Neoplasms 5Endometrial Neoplasms 4Ovarian Neoplasms 3Solid Tumors 2Prostatic Neoplasms 2Multiple Myeloma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Solid Tumor 1Primary Myelofibrosis 1Osteosarcoma 1Myelodysplastic Syndromes 1Liposarcoma 1Leukemia 1Leiomyosarcoma 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Bone Neoplasms 1Advanced Cancers 1

Interventions

Doxorubicin 25Gemcitabine 16Trabectedin 12Ifosfamide 12Radiotherapy 11Docetaxel 10Dacarbazine 8pazopanib 7Nivolumab 6Specimen Handling 5liposomal doxorubicin 4Temozolomide 4Biopsy 4pembrolizumab 3Sunitinib 3Sorafenib 3Radiation 3Magnetic Resonance Spectroscopy 3Filgrastim 3rucaparib 2pegfilgrastim 2olaratumab 2eribulin 2durvalumab 2cixutumumab 2cemiplimab 2brostallicin 2belinostat 2avelumab 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Leiomyosarcoma × ridaforolimus × Clear all
NCT00093080 2015-02-13

Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 2 Completed
216 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Neoplasm Metastasis, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡